Avantor (NYSE:AVTR) Hits New 52-Week Low - What's Next?

Avantor, Inc. (NYSE:AVTR - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $17.14 and last traded at $17.73, with a volume of 7219151 shares trading hands. The stock had previously closed at $17.35.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Raymond James restated an "outperform" rating and set a $24.00 price target (down previously from $26.00) on shares of Avantor in a research note on Monday, February 10th. Morgan Stanley cut their price objective on shares of Avantor from $27.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. Stifel Nicolaus lowered their target price on shares of Avantor from $28.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, February 10th. Robert W. Baird cut their price target on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a report on Monday, October 28th. Finally, Royal Bank of Canada lowered their price objective on Avantor from $33.00 to $31.00 and set an "outperform" rating on the stock in a report on Monday, February 10th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.92.

Avantor Trading Down 1.1 %

The firm has a market cap of $11.78 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 1.59 and a beta of 1.28. The business has a fifty day moving average of $21.06 and a two-hundred day moving average of $23.01. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.70 and a current ratio of 1.07.

Avantor (NYSE:AVTR - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter in the prior year, the business earned $0.22 EPS. As a group, equities analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avantor

Several hedge funds have recently added to or reduced their stakes in AVTR. Mackenzie Financial Corp grew its position in shares of Avantor by 33.0% in the fourth quarter. Mackenzie Financial Corp now owns 43,358 shares of the company's stock valued at $914,000 after purchasing an additional 10,764 shares during the last quarter. Forum Financial Management LP acquired a new stake in Avantor during the 4th quarter valued at $417,000. Toronto Dominion Bank increased its position in Avantor by 6.9% during the fourth quarter. Toronto Dominion Bank now owns 88,812 shares of the company's stock worth $1,871,000 after buying an additional 5,748 shares in the last quarter. North Star Asset Management Inc. increased its position in Avantor by 8.9% during the fourth quarter. North Star Asset Management Inc. now owns 236,582 shares of the company's stock worth $4,985,000 after buying an additional 19,407 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Avantor in the fourth quarter worth $2,116,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.